Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults

Philippe Lesprit, Gaëlle Pédrono, Jean Michel Molina, Cécile Goujard, Pierre Marie Girard, Nathalie Sarrazin, Christine Katlama, Patrick Yéni, Pascale Morineau, Jean François Delfraissy, Geneviève Chêne, Yves Lévy*, P. Lesprit, Y. Levy*, N. Sarrazin, G. Pedrono, C. Rabian, P. Bursachi, M. J. Commoy, J. F. DelfraissyF. Denis, B. Fritzell, C. Goujard, R. Salamon, R. Tubiana, J. P. Viard, A. Krivitzky, M. Bentata, S. Makki, R. Mansouri, L. Guillevin, B. Jarousse, A. K. Klutse, G. Obenga, P. Honoré-Berlureau, Y. Baazia, S. Soreda, J. P. Clauvel, E. Oksenhendler, L. Gerard, J. Delgado, J. M. Molina, N. Colin De Verdière, P. Palmer, I. Madelaine, M. Dupon, J. M. Ragnaud, D. Neau, I. Raymond, I. Garrigue, J. P. Dupin, Ch Boitard, J. P. Viard, S. El Marsafy, R. Lahoulou, A. Mogenet, C. Broissand, J. F. Delfraissy, C. Goujard, D. Pereti, Y. Quertainmont, P. Robquin, O. Segeral, S. Poirier, M. T. Rannou, N. Idri, C. Le Tiec, D. Sicard, D. Salmon, O. Launay, B. Silbermann, C. Desaint, A. Krivine, C. Guérin, A. Sobel, Y. Lévy*, P. Lesprit, A. S. Lascaux, Ch Chesnel, C. Jung, A. Miladi, C. Antoine, F. Bricaire, I. Boubezari, S. Pierre-François, L. Schneider, C. Seulié, M. H. Fievet, P. M. Girard, A. M. Béglé, F. Besse, R. Mouchotte, A. Charrois, A. Duaguenel-Nguyen, P. Yeni, I. Fournier, S. Lariven, B. Phung, P. Ralaïmazava, Ch Gaudebout, J. Gerbe, D. Descamps, S. LePoole, J. Reynes, P. André, V. Baillat, V. Le Moing, C. Merle, M. Vidal, J. M. Fondère, I. Roch-Torreilles, F. Raffi, P. Morineau, C. Allavena, B. Bonnet, H. Hue, E. Guarnier, A. Lepelletier, P. Perré, O. Aubry, S. Leautez, C. Leroy, I. Suaud, A. S. Poirier, A. Lepelletier, P. Dellamonica, V. Rahelinirina, M. A. Sereni, S. Benhamou, M. Ch Rigault, P. Massip, B. Marchou, M. Alvarez, E. Bonnet, L. Cuzin, M. Obadia, F. Balsarin, M. Barone, M. Heraud, I. Peyranne, F. Mentré, P. Morlat, N. Sarrazin, G. Pedrono, I. Tschöpe, G. Palmer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: To evaluate whether a strategy combining a prime with a 7-valent conjugate pneumococcal vaccine (PCV) followed by a boost with the 23-valent polysaccharide vaccine (PPV) would improve immunogenicity against Streptococcus pneumoniae polysaccharides in HIV-infected patients. DESIGN: Randomized controlled phase II trial. METHODS: Two-hundred and twelve patients with CD4 cell counts of 200-500 cells/μl and HIV RNA< 4 log10 copies/ml, regardless of antiretroviral treatment, were randomized to receive either PCV at week 0 and PPV at week 4 (n = 106) or PPV alone at week 4 (n = 106). The proportion of responders to 0, 1-2, 3-4, 5-7 serotypes shared by the two vaccines was evaluated at week 8 and compared using a proportional odds model allowing for adjustment for CD4 cell count, HIV RNA and antiretroviral treatment. RESULTS: At week 8, the profile of response was better in the prime-boost group compared to the PPV group, as determined by the frequency of patients who reached both a twofold increase of serotype-specific IgG levels and IgG level ≥ 1 μg/ml [proportional odds ratio (OR), 2.09; 95% confidence interval (CI), 1.25-3.51; P = 0.005]. No differences in responders were found 4 weeks after PCV or PPV alone, suggesting that PCV primed for response to PPV. Early differences between groups remained significant at week 24 (proportional OR, 2.14; 95% CI, 1.30-3.54; P = 0.003). CONCLUSIONS: In a setting of practical care, a PCV prime-PPV boost strategy enhances the frequency, breadth and magnitude of antibody responses against SPP in HIV-infected adults.

Original languageEnglish
Pages (from-to)2425-2434
Number of pages10
Issue number18
StatePublished - Dec 2007
Externally publishedYes


  • Conjugate vaccine
  • HIV
  • Immunogenicity
  • Pneumococcal vaccine
  • Priming


Dive into the research topics of 'Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults'. Together they form a unique fingerprint.

Cite this